Case report {#s0010}
===========

A 49-year-old man was found to have spitzoid-type Clark level 4 malignant melanoma of the posterior left calf with locally advanced, node-positive disease. He underwent wide local excision of the lesion with left inguinal sentinel lymph node biopsy and was started on ipilimumab immunotherapy. Three months after beginning the treatment, he presented to the emergency department with headache and nausea. Laboratory analysis showed several hormonal abnormalities, including depressed luteinizing hormone of 0.9 mIU/mL (normal, 1.7-8.6 mIU/mL), testosterone \<3 ng/dL (normal, 348-1197 ng/dL), cortisol 1.71 mcg/dL (normal, 6.02-18.4 mcg/dL), and thyroid-stimulating hormone of 0.04 (normal, 0.27-4.20 mcU/mL).

Magnetic resonance imaging (MRI) of the brain was performed and showed a solitary heterogeneously enhancing sellar mass ([Fig. 1A](#f0010){ref-type="fig"}). Within the sellar mass, a well-defined T2-hyperintense focus that did not completely suppress on fluid attenuation inversion recovery imaging (T2 FLAIR) ([Fig. 1E](#f0010){ref-type="fig"}), indicative of proteinaceous fluid, potentially subacute hematoma. The differential diagnosis for this lesion was a hemorrhagic melanoma metastasis versus an atypical "cystic" presentation of ipilimumab-induced hypophysitis.Fig. 1Magnetic resonance imaging of the pituitary gland after 2 cycles of ipilimumab obtained in the setting of new headache. Sagittal T1 precontrast (A), sagittal T1 postcontrast (B), and coronal T1 postcontrast (C) images demonstrate a 1.5 cm heterogeneously enhancing mass filling the sella and extending into the suprasellar cistern and up the pituitary infundibulum to abut the undersurface of the midportion of the optic chiasm. Axial T2 (D), axial T2 fluid attenuation inversion recovery (E), and coronal T2 (F) images demonstrate a 7 mm pocket of fluid signal within the sellar portion of the mass, likely representing a small internal subacute hematoma versus other proteinaceous fluid.Fig. 1

This diagnosis presented a therapeutic dilemma because surgical resection is typically the therapy for hemorrhagic pituitary metastasis causing acute symptoms; whereas, the treatment for ipilimumab-induced hypophysitis is to withdraw the medication and assess for regression of the hypophysitis. In this case, despite the atypical imaging features, a conservative approach was pursued, mainly because the patient\'s symptoms were not severe enough to necessitate urgent surgical intervention. The patient discontinued the ipilimumab, and underwent corticosteroid therapy to treat the potential ipilimumab-induced hypophysitis. His headaches resolved within a few days, and a repeat MRI one month later showed significant improvement, with only a small focus of residual abnormal T2 signal in the pituitary gland ([Fig. 2A](#f0015){ref-type="fig"}). The infiltrative and enlarged appearance of the pituitary had resolved ([Fig. 2B](#f0015){ref-type="fig"}).Fig. 2One-month follow-up magnetic resonance imaging of the pituitary gland after the ipilimumab was given and corticosteroid therapy was initiated. Axial T2 fluid attenuation inversion recovery (A) and sagittal T1 postcontrast (B) images demonstrate resolution of sellar mass with only a small focus of residual T2 signal abnormality.Fig. 2

Discussion {#s0015}
==========

Ipilimumab (Yervoy; Bristol-Myers Squibb, New York, NY) is a human monoclonal antibody that acts as a CTLA-4 receptor blocker, potentiating the cytotoxic T-cell response to tumor cells and increasing the propagation of T-cell populations. Although this mechanism does not specifically target any tumor marker unique to melanoma, T cell augmentation amplifies the patient\'s own immune response to the cancer cells [@bib0010]. In 2011, ipilimumab was fast-track FDA-approved for the treatment of metastatic melanoma due to its promising results in phase 3 experimental trials [@bib0015]. The drug demonstrated improved overall survival in patients with metastatic melanoma with a 1-year survival rate of 46% in those taking ipilimumab, versus 22-38% with the various other therapies available [@bib0020].

Hypophysitis has been well documented as a potential complication of ipilimumab in up to 11% of patients in 1 retrospective cohort [@bib0025]. The diagnosis can be challenging due to the wide range of potential imaging features, which include diffuse enlargement of the pituitary gland, enlargement of just the pituitary infundibulum, and variable enhancement patterns from focal and homogeneous to diffuse and heterogeneous [@bib0030], [@bib0035], [@bib0040].

To date, there are no reports of hypophysitis with cystic imaging features in patients taking ipilimumab. The cystic appearance makes the differentiation of hypophysitis from metastatic disease more difficult because internal hemorrhage is reasonably common in melanoma metastatic to the pituitary gland. In our patient, the symptoms were not severe enough to necessitate immediate surgical intervention, and the reasonable possibility of an atypical presentation of ipilimumab-induced hypophysitis warranted a conservative approach. Once the ipilimumab was discontinued and corticosteroids were administered, the pituitary lesion resolved, and the diagnosis of an atypical presentation of ipilimumab-induced hypophysitic with "cystic" features was confirmed.
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